Opengear Launches CM8100 Console Manager Enabling Simplified Device Management at Scale for Data Centers
7.6.2022 15:00:00 EEST | Business Wire | Press release
Opengear, a Digi International company (NASDAQ, DGII, www.digi.com/) and leading network resilience solutions provider, announced today that it is launching its new family of console managers, the CM8100. As the latest addition to its award-winning Smart OOBTM Console Server family, the CM8100 delivers a comprehensive solution, adding NetOps capabilities to existing Smart OOB features that simplify connectivity to IT equipment. Moreover, it provides resilient and secure remote access to infrastructure devices while enhancing security and automation for better smart out-of-band management.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220607005005/en/
As the latest addition to its award-winning Smart OOB Console Server family, Opengear's CM8100 delivers a comprehensive solution, adding NetOps capabilities to existing Smart OOB features that simplify connectivity to IT equipment. Moreover, it provides resilient and secure remote access to infrastructure devices while enhancing security and automation for better smart out-of-band management. (Photo: Business Wire)
“IT infrastructure needs to be resilient and easy to manage without relying on the network to manage the network,” says Gary Marks, President of Opengear. “Whether IT teams need to bring up new devices, manage existing ones or remediate outages, they must have resilient access to the network from anywhere. Regardless of the state of the production network, Opengear’s CM8100 provides engineers with the remote and reliable connectivity they need to be successful. It is yet another milestone in our long line of solutions designed to help engineers overcome today’s challenges such as travel requirements, security restrictions, and a lack of connectivity.”
CM8100 highlights:
- Hosts up to 48 managed serial connected devices
- Hardware-based TPM 2.0 security module providing data encryption and secure boot
- Open architecture REST API based firmware supporting automation tools, Docker, and Python scripting
- Four times faster than the previous generation while maintaining power-efficient and passively cooled operation up to 50C
- Dual AC power supplies with independent monitoring and alerting
The Opengear platform and CM8100 enhance console access with modern automation capabilities. The CM8100 also helps IT personnel remotely provision, manage and remediate devices. Likewise, it enables remote access to even the most sprawling and complex infrastructure, such as switches, routers, PDUs, firewalls, and other critical data center equipment. Additionally, CM8100 appliances establish secure VPN tunnels which connect IT, staff, to remote devices. This provides local access to Ethernet and RS-232 console ports via standard UTP patch cables. The resilient connection of the CM8100 is available to either IT staff or applications to configure managed devices.
“Nearly every enterprise is familiar with the ‘3 a.m.’ call about a down server or a network device but driving or even flying to a data center or remote site can be time-consuming and expensive,” adds Marks. “More than half of IT outages cost over $100,000, so network issues must get fixed quickly. However, if engineers can’t access the network remotely and lack visibility, they will arrive at the site without the right tools or replacement devices to be successful in one trip. With the Opengear platform, IT personnel have the visibility to ascertain the problem from afar and also the access to remediate the outage remotely, saving considerable time and resources.”
For more information about the CM8100, visit https://opengear.com/products/cm8100-console-server/.
To learn more about Opengear, visit: www.opengear.com.
About Opengear
Opengear, a Digi International company, delivers secure, resilient access and automation to support critical IT infrastructure, even when the network is down. Provisioning, orchestration, and remote management of network devices through innovative software and appliances enable technical staff to reliably and efficiently manage data centers and remote network locations. Opengear solutions are trusted by global organizations across financial, digital communications, retail and manufacturing industries. The company is headquartered in New Jersey, with R&D centers in Silicon Valley and Brisbane, Australia. Opengear was acquired by Digi International in 2019, bringing together two organizations with a deep commitment to providing the best products, software and services that meet the demands of mission-critical networks. For more information, please visit www.opengear.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220607005005/en/
Contact information
Opengear Contact
Peter Ramsay / Lora Metzner
Global Results Communications
open@globalresultspr.com
949.307.5908
UK/Ireland/Scotland: Opengear Media Relations Contact – Whiteoaks International
Kate Hellig
kateh@whiteoaks.co.uk
+44 (0) 1252 727313 (ext 124)
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
